UK markets closed

Spectrum Pharmaceuticals, Inc. (SPPI)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
1.2300-0.1800 (-12.77%)
As of 01:42PM EDT. Market open.

Yahoo Finance will soon be upgrading our Conversations message board platform to provide a better experience for our users. Only comments published since April 21, 2021 will be visible on Yahoo Finance after the upgrade. If you wish to download and save any of your older comments, please submit a request via the Privacy Dashboard by no later than Aug. 15, 2022.

Sign in to post a message.
  • d
    dcaf7
    Hanmi to start confirmatory NSCLC trial of poziotinib in Korea
    On Tuesday, the Ministry of Food and Drug Safety authorized Hanmi to conduct the local phase 3 study of poziotinib (ingredient: poziotinib hydrochloride) in patients with locally advanced or metastatic NSCLC who have been previously treated and who have HER2 exon 20 insertion mutations.
    http://www.koreabiomed.com/news/articleView.html?idxno=14405
  • d
    dcaf7
    From recent discussion about Enhertu and Poziotinib.
    Benjamin Levy, MD:Let’s move to HER2 [human epidermal growth factor receptor 2]. HER2 mutations; maybe 2% to 5% of all lung cancer, lung adenocarcinoma and we have some new therapies here, Jonathan. For the sake of time trastuzumab emtansine is a drug presented by Bob Li with a response rate of roughly 40%, and a PFS [progression-free survival] around 5 to 6 months. We’ve got poziotinib, which is a pretty toxic drug but has a response rate I think of 30% to 40% but perhaps what’s leading the way is trastuzumab deruxtecan. Do you want to walk us through those data and the importance of this? To me this 1 is on the leading edge and is practice changing.

    Jonathan Wesley Riess, MD: The trastuzumab deruxtecan data are very impressive: very good response rate, very good progression-free survival. There are pitfalls to cross-trial comparisons but numerically it appears to be better than many other agents that have reported out clinical trials. It’s got its own unique adverse effect profile, but it’s something I’ve used. It’s not FDA approved, but it’s something I definitely use. I have seen activity and would even consider it potentially in the first-line setting. But then you look at poziotinib. There are data regarding poziotinib that have been presented. It does have a pretty good response rate. The PFS—again, a cross-trial comparison of the pitfalls—seems a bit less than trastuzumab deruxtecan. It’s a tough drug in terms of adverse effects such as diarrhea and rash. That’s where some of these drugs have a therapeutics index issue in terms of toxicity vs maintaining a dose that would give a benefit in terms of PFS and tumor shrinkage.
  • n
    ngotpwned
    Next support 1.302, if that breaks I think downtrend begins. Don’t know how far it will go, keep in mind huge catalysts coming traders have been playing w/ volatility. So I wouldn’t be worried, end of day price action next month only matters for insurance if we get denial. If we get approved doesn’t matter if we go $0.7 or stay at $1.4. If we have P/S of 5 with $400M in sales from rolontis we looking at $11 stock
  • R
    Rex
    Day 7 of 10. Another great day
  • R
    Rex
    Day 8 of 10. Yucky day, but we are close.
  • R
    Real Joe
    think that is the dip to buy
  • j
    jeff
    We might see an early rolontis approval
  • j
    jeff
    On rolontis approval let’s see who guesses the closest the stock goes the highest. I’m predicting 6. Then it drops but on poziotinib approval 23
  • 2
    2barare
    Buying opportunities yay
  • n
    ngotpwned
    Volume was interesting today, lots of volume holding it’s at $1.40. We were around 2M shares traded after the initial -9% and then 3.8M shares were traded keeping it static. Must be huge war between big buyers/or lots of retailers vs. Shorts. Don’t rly know if it’s good, but we had on .90 just above avg volume, then 3m, 4m and then 5.8m on this down day. But keep in mind 3.8m of that volume was stabilizing at $1.4 support. Tomorrow’s volume will be very important.
  • r
    reppeptgs
    This is fun. We know it won’t last forever, but wow – this IS fun.

    Let’s look at the numbers. SPPI ended green in 4 out of 5 sessions, which makes it 9 out of the last 10. By Friday’s closing bell, the stock was up 30 cents or 28.3%, to close at a robust $1.36. The stock traded for over a buck the whole week. Last time that happened? The week of 4/4.

    Notably, the market did not provide a whole lot of support. The NAS was down in 3 of 5 sessions, but still closed the week with a gain of 3.08%. Its loss on the year improved from 20.8% to 16.6%.

    The DOW was actually green in 4 of 5 sessions, but still couldn’t keep up with the NAS , as it ended with a gain of 2.92%. Its loss on the year shrunk from 9.85% to 7.22%. Better.

    BA was on pace with the DOW, as it gained 2.99% to close at $169.99. Its loss on the year was trimmed to 15.5%.

    My bio indexes were mixed. The BTK actually closed red on the week by 0.89%; the IBB was green, but only by 0.82%; the XBI managed a modest gain of 1.7%. Somewhat surprisingly, the XLV had the second highest gain of the bunch, at 1.65%.

    The Russell 2000 was head and shoulders above the rest, surging 4.93%.

    Last August 13, SPPI closed at $2.35 (last week, the comparison was $3.25). The YoY loss plunged from 67.3% to 42.1%! Finally – for the first time in...I don’t know how long, this comparison is less than a 50% loss.

    Here are the daily ranges from this week:

    M 1.06-1.14
    T 1.01-1.12
    W 1.00-1.12
    Th 1.20-1.29
    F 1.22-1.38

    And from last week:

    M 0.82-0.85
    T 0.82-0.87
    W 0.84-0.93
    Th 0.87-0.94
    F 0.94-1.12

    Writing these weekly summaries makes me stand back and take a look at the market and this investment. If I don’t do that, it would be too easy to lose perspective.

    The market did not provide a lot of support. It didn’t hurt, but there certainly was no tailwind. This week, for SPPI, the tailwind was the earnings report.

    Huh?

    How often can that be said about a pharma development company?

    But that’s the truth. SPPI reported that it’s close to making money on the drug formerly known as Rolontis. And Pozi is showing success in some types of cancer that have been resistant to all other treatments…and the tox issue seems, finally, to be manageable.

    Importantly, the market has noticed. Volume surged to almost twice its average levels in the last 3 sessions of the week. While the market was not a great help, at least it wasn’t a hindrance.

    In the next session or two, it would be nice to see the stock close above $1.40, and trade above $1.44. These would confirm the up-trend, even if the stock backed off a bit afterward. Those levels, BTW, were also from early April.

    Congrats, longs, on your patience. Extra congrats to those who added when the stock was under a buck.

    This has been a great two weeks. Let’s hope it lasts a while longer.

    Sarge
  • S
    StockKing
    Volume looks good, Price looks good. Support too. Hmmmmm.
  • R
    Rex
    Day 6 of 10. Another good day
  • J
    Johnny R
    lot of positive info coming from the earnings call. One mystery they solved for me is the sales force. They have a commercial launch structure/sales force already in place and that is apparently why the job openings on the website disappeared a while back . . . . because they filled the positions. they now have posted an additional 20 openings to get the sales force up to 40. They kind of alluded that the move to Boston was to take advantage of all the pharma sales/marketing talent available in the area. Bring on 9/9 !!
  • L
    Luquman
    today after 4pm Will publish
  • S
    Skipper1072
    We were due for a statistical correction.
  • d
    dcaf7
    Poziotinib data will be presented at ESMO 2022 in September, "1172P - High Activity of Poziotinib in G778_P780dup HER2 Exon 20 Insertion Mutations in Non-Small Cell Lung Cancer (NSCLC)".
    As I remember, high activity for this mutation is ORR of 100%.
  • L
    Luquman
    trader out
    only investers NOW 😂😂😂😂
  • R
    Rex
    Day 4 of 10
  • d
    dcaf7
    Morning call was positive. Good to know that they are still considering same day Efla trial as life cycle management.